Preparation and partial pharmacodynamic studies of luliconazole ethosomes.

Clin Exp Pharmacol Physiol

Department of Dermatology, the Frist Medical Centre, Chinese PLA General Hospital, Beijing, China.

Published: May 2022

As a drug carrier, ethosome is found to be efficient in delivering drug to the deep skin layers through stratum corneum, and the purpose of this paper is to develop luridazole ethosomes acting as an optimal choice for transdermal antifungal drugs. The luliconazole ethosomes were prepared by thin-film hydration, and evaluated for morphology, size, entrapment efficiency (EE), stability and deformability. In vitro, the transdermal experiment was performed on excised rat skin by Franz diffusion cell, and minimum inhibitory concentration (MIC) was applied to determine antifungal activity. In vivo, the irritation of luliconazole ethosomes was also observed in rats. The luliconazole ethosomes were prepared with 5% (w/v) lecithin, 45% (v/v) ethanol and 8-min ultrasound, and characterised with small and uniform particle size, high EE of about 70%. These ethosomes possessed good deformability, were stable and affected by light and high temperature. The cumulative amount permeated of different dosage forms at 48 h from high to low was: ethosome > ointment > liposome > hydroalcoholic solution (p < 0.05), and the sum of the luliconazole retention of skin from high to low at 48 h was: ethosome/ointment > liposome > hydroalcoholic solution (p < 0.05). In the antifungal experiment, the MICs from high to low were: hydroalcoholic solution > liposome > ethosome (p < 0.05), and Trichoderma was more sensitive to luliconazole than Candida. There was no skin irritation observed after treatment of luliconazole ethosomes. The luliconazole ethosomes are firstly prepared in our study, which have little stimulation, better permeation effect and antifungal activity, offering a new perspective for choosing clinical antifungal drugs in the Department of Dermatology.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1440-1681.13623DOI Listing

Publication Analysis

Top Keywords

luliconazole ethosomes
16
ethosomes prepared
8
ethosomes
6
preparation partial
4
partial pharmacodynamic
4
pharmacodynamic studies
4
luliconazole
4
studies luliconazole
4
ethosomes drug
4
drug carrier
4

Similar Publications

Preparation and partial pharmacodynamic studies of luliconazole ethosomes.

Clin Exp Pharmacol Physiol

May 2022

Department of Dermatology, the Frist Medical Centre, Chinese PLA General Hospital, Beijing, China.

As a drug carrier, ethosome is found to be efficient in delivering drug to the deep skin layers through stratum corneum, and the purpose of this paper is to develop luridazole ethosomes acting as an optimal choice for transdermal antifungal drugs. The luliconazole ethosomes were prepared by thin-film hydration, and evaluated for morphology, size, entrapment efficiency (EE), stability and deformability. In vitro, the transdermal experiment was performed on excised rat skin by Franz diffusion cell, and minimum inhibitory concentration (MIC) was applied to determine antifungal activity.

View Article and Find Full Text PDF

Herbal ethosomal gel containing luliconazole for productive relevance in the field of biomedicine.

3 Biotech

March 2020

Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan 304022 India.

This study includes development, characterization, and optimization of herbal ethosomal formulation. The aim of the present study is to develop drug loaded ethosomes capped with (neem) which, was further incorporated in Carbopol 934 K thereby, resulting in the formation of ethosomal gel. The formulation is aimed to express effective treatment against fungal infection.

View Article and Find Full Text PDF

Luliconazole is a new drug candidate for treatment of topical fungal infections. Its present therapy is associated with limitations of very poor and slow skin permeation, leading to required long term repeated administration for complete cure of disease. Lipid nanocarriers based elastic lipogel and ethogel formulations were developed in strength of 1% w/w and extensively characterized , , and and compared for their results to the marketed formulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!